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Abstract:
BACKGROUND: The first cases of the coronavirus disease 2019 (COVID‑19) were reported in 
Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy. 
However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe 
treatment option for COVID‑19 patients with both moderate and severe disease.
OBJECTIVE: The aim of the present meta‑analysis was to investigate whether remdesivir was 
effective for treating COVID‑19 including reduced in‑hospital adverse events, oxygen support, and 
mortality rates.
METHODS: According to the PRISMA reporting guidelines, a review was conducted from 
January 1, 2020, until August 25, 2020, with MeSH terms including COVID‑19, COVID, coronavirus, 
SARS‑CoV‑2, remdesivir, adenosine nucleoside triphosphate analog, and Veklury using MEDLINE, 
Scopus, and CINAHL Plus. A modified Delphi process was utilized to include the studies and ensure 
that the objectives were addressed. Using dichotomous data for select values, the unadjusted odds 
ratios (ORs) were calculated applying Mantel–Haenszel random‑effects method in Review Manager 5.4.
RESULTS: Randomized controlled trials pooled in 3013 participants with 46.3% (n = 1395) in the 
remdesivir group and 53.7% (n = 1618) in the placebo group. The placebo group had a higher risk of 
mortality as compared to the intervention group with significant OR (0.61) (95% confidence interval 
of 0.45–0.82; P = 0.001). There was minimal heterogeneity among the studies (I2 = 0%).
CONCLUSIONS: Our findings suggest that remdesivir extends clinical benefits by reducing mortality, 
adverse events, and oxygen support in moderate to severely ill COVID‑19 patients. Concerted efforts 
and further randomized placebo‑controlled trials are warranted to examine the potency of antiviral 
drugs and immunopathological host responses contributing to the severity of COVID‑19.
Keywords:
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Introduction
Since the first cases of the coronavirus disease 2019 (COVID‑19) were reported in 
Wuhan, Hubei Province, China, in December 
2019, a large‑scale spread internationally 
led the World Health Organization (WHO) 
to declare COVID‑19 as a public health 
emergency of international concern on 
January 30, 2020.[1] Antiviral treatment options 
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of proven clinical efficacy in COVID‑19 infections are 
under investigation.[2] Remdesivir is an investigational 
nucleotide prodrug which intracellularly metabolizes 
to the active nucleoside triphosphate and interferes 
with viral RNA‑dependent RNA polymerase activity, 
thereby disrupting viral exoribonuclease activity.[3] 
However, the pharmacokinetics of remdesivir within 
the respiratory tract of critically ill COVID‑19 patients 
are not well known. Hospitalized COVID‑19 patients 
with oxygen saturation ≤94% on room air or requiring 
oxygen support are eligible to receive remdesivir under 
the US Food and Drug Administration (FDA) emergency 
use authorization (EUA).[4] While previous studies have 
reported a reduction in median time to clinical improvement, 
insufficient power of sample sizes limited the deductibility 
of clinical outcomes of remdesivir.[5] In addition, initiating 
remdesivir earlier in the COVID‑19 treatment protocols 
must be considered before immune‑mediated epithelial 
damage due to the fact that elevated viral replication occurs 
and may reduce mortality and disease severity as observed 
previously in severe acute respiratory syndrome (SARS) 
and Middle East respiratory syndrome (MERS).[6]
Based on the preliminary reports and findings from 
in vitro and in vivo activity in animal models of 
SARS‑CoV‑1 and MERS‑CoV, remdesivir treatment for 
5 or 10 days is being administered to COVID‑19 patients 
with comparable efficacy and safety.[7‑9] While most 
COVID‑19 infections are self‑limiting, some individuals 
may contract severe disease warranting increased length 
of hospital stay and ventilator support, which places 
burden on health infrastructures.[10] Use of remdesivir 
has resulted in reduced oxygen support in a cohort with 
53 hospitalized COVID‑19 patients.[11] Consequently, 
with revised recommendations suggesting uncertain 
efficacy of remdesivir and benefits among patients 
already on high‑flow oxygen, mechanical ventilation, 
or extracorporeal membrane oxygenation (ECMO), the 
initiation and duration of remdesivir treatment among 
COVID‑19 hospitalized patients receiving oxygen support 
remain unclear.[12] Given the uncertainty on the beneficial 
outcomes of remdesivir‑treated COVID‑19 patients, we 
aimed to examine the following differences between 
remdesivir and placebo groups: (1) oxygen support status 
at day 1 and day 14, (2) any adverse events at day 14, 
and (3) death from any cause at day 14.
Methods
Search strategy
According to the PRISMA reporting guidelines, a review 
was conducted from January 1, 2020, until August 6, 2020, 
with MeSH terms including “COVID‑19,” “coronavirus,” 
“SARS‑CoV‑2,” “COVID,” “remdesivir,” “adenosine 
nucleoside triphosphate analog,” “Veklury” using 
Medline, Scopus, and CINAHL Plus. Quantitative primary 
research articles were added to the systematic review 
and meta‑analysis. The inclusion criteria of the included 
studies were having COVID‑19–infected patients aged 18 
or older being treated with remdesivir  and/or placebo. 
Duplicates were removed using EndNote X9 a reference 
management software package developed by Clarivate 
Analytics. We manually cross‑checked the searches for 
authors, title, and abstract to remove duplicates.
Two investigators (AS and ZS) independently 
screened the titles and abstracts before reaching to a 
consensus to determine the included studies. The third 
investigator (MSG) was present for any disagreements. 
Exclusion criteria were applied to full texts during the 
final selection. A modified Delphi process was used to 
include studies and to ensure that our objective was 
identified in selected studies .[13] The a priori methods 
for conducting the Delphi process for meta‑analyzing 
the clinical effectiveness are described in Figure 1. We 
included studies if they were randomized control trials, 
they had an intervention arm as compared to placebo, 
and the end point of interest was clinical outcomes and 
mortality. Two investigators (AS and ZS) re‑confirmed 
all data entries and checked imported data from all 
studies at least thrice for accuracy.
Box‑ED
What do we know about remdesivir (Veklury) for 
coronavirus disease 2019 so far?
• Remdesivir is an antiviral drug, which has shown 
promise in randomized controlled trials for 
coronavirus disease 2019 (COVID‑19)
• The extended emergency use authorization by the 
US Food and Drug Administration has promoted 
its use among hospitals in the US and worldwide.
Why is this important for readers?
• The role of remdesivir as an experimental drug has 
been promising during the COVID‑19 pandemic
• The drug will likely to be the best antiviral choice of 
treatment for all moderate and severe SARS‑CoV‑2 
infections.
How is this study structured?
• This is a meta‑analysis study which includes 
data from 3013 patients who were administered 
remdesivir for 5 and 10 days.
What does this study inform us about?
• Remdesivir extends clinical benefits in hospitalized 
patients by reducing mortality, adverse events, and 
the requirement for oxygen support
• Ongoing efforts are required by conducting randomized 
placebo‑controlled trials across the world.
• The potency of the antiviral drug, remdesivir, must be 
examined along with testing immunopathological 
host responses contributing to the severity of 
COVID‑19.
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Quality assessment
We evaluated the risk of bias for all included studies 
using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) criteria.[14] 
We aimed to evaluate the risk of bias associated with 
the selection of participants, confounding, and health 
outcome assessment. In doing so, we found the risk 
of bias of all four individual studies included for 
quantitative analysis using the GRADE criteria. Since 
less than 10 studies were included, we did not check for 
publication bias using funnel plots.
Outcomes
The primary outcomes included death from any cause 
at day 14. The secondary outcomes were to identify 
any adverse events at day 14 of the treatment and the 
requirement for supplemental oxygen, high‑flow nasal 
cannula, noninvasive ventilation, invasive ventilation, 
or ECMO at day 1 and 14. The time to recovery in days, 
total patients recovered, and findings of serious adverse 
effects among remdesivir and placebo groups were 
identified.
Data analysis
Two independent reviewers (AS and ZS) assessed 
the eligibility of all full‑text articles; the third (MSG) 
arbitrated for cases to reach a consensus. The first 
reviewer (AS) extracted the data, and the second 
reviewer (ZS) validated the data extraction for all studies. 
The quantitative data were entered into a spreadsheet. 
If more than one study reported data on posttreatment 
outcomes, data were extracted separately for each study. 
We independently extracted data from the published 
randomized placebo‑controlled trials.
Using dichotomous data for select values, summary 
measures namely the unadjusted odds ratios (ORs) were 
calculated using the Mantel–Haenszel random‑effects 
methods. We calculated the ORs and 95% confidence 
intervals (CIs) for each measure evaluated in two or more 
studies. A meta‑analysis was conducted using Review 
Manager V.5.4 the desktop version of the software 
used for review formats (diagnostic, methodology, 
overviews), for non‑Cochrane reviews, and for offline 
working, developed by Cochrane Training. Findings 
were presented using 95% CIs along with the I2 test for 
heterogeneity between studies.
Source of funding
No funding was obtained for the purpose of this study.
Results
The search process is shown in Figure 2. The initial 
screening yielded 1242 results. After the exclusion of 
duplicates, 946 results were withheld for the screening 
of title and abstract. Consequently, 704 records were 
excluded due to ineligibility (reviews, editorials, 
non‑random controlled trials, ongoing trials, and 
abstracts). Finally, after screening 242 full‑text articles, 
only four studies reporting 3013 patients (remdesivir 
n = 1395; placebo n = 1618) were included in the 
qualitative and quantitative syntheses. While three out 
of four studies were of high quality based on the GRADE 
scale, Olender et al.’s study was graded moderate.[15]
Mortality at day 14 of treatment
All four studies reported the data on mortality at day 14 
and thus were eligible to be included in the meta‑analysis. 
Compared with the remdesivir‑treated group, the 
placebo group had higher risks of mortality (OR: 0.61; 
95% CI: 0.45–0.82; P = 0.001) [Figure 3]. For the sensitivity 
analysis, we tested if the removal of study by Beigel 
et al. would lead to changes in the OR and significance. 
After excluding this study, the results suggested that the 
risk of mortality was still higher in the placebo group 
(OR: 0.66; 95% CI: 0.44–0.98; P = 0.04), with homogenous 
findings (I2 = 0%).
Supplemental oxygen at day 1 and 14 of treatment
All four studies presented the data of supplemental 
oxygen requirement at day 1 of treatment among the 
remdesivir and placebo groups. Using a random‑effects 
model, we determined that the remdesivir group 
had similar odds as compared to the placebo group 
in requiring supplemental oxygen at the 1st day of 
treatment (OR: 1.03; CI: 0.87–1.23; P = 0.70), with limited 
heterogeneity among all studies (I2 = 8%) [Figure 3].
Figure 1: Modified Delphi Process
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Three out of four studies evaluated the supplemental 
oxygen use at day 14 of the treatment among the 
remdesivir group and the placebo group. However, 
there was a higher likelihood of the placebo group to 
require supplemental oxygen at the end of the 2nd week 
of treatment (OR: 0.88; CI: 0.62–1.24; P = 0.46), with no 
heterogeneity among the studies (I2 = 1%) [Figure 3].
High‑flow nasal cannula or noninvasive 
mechanical ventilation at day 1 and 14 of 
treatment
All four studies presented the data of high‑flow nasal 
cannula or noninvasive mechanical ventilation required 
at day 1 of treatment. Patients in the placebo group 
as compared to the remdesivir group had high odds 
of requiring high‑flow nasal cannula or noninvasive 
mechanical ventilation (OR: 0.81; CI: 0.64–1.04; P = 0.10; 
I2 = 9%) [Figure 3].
Three of the four studies presented the requirements 
of  h igh‑f low nasal  cannula  or  noninvasive 
mechanical ventilation at day 14 of treatment. 
The likelihood of the placebo group was higher 
as compared to the remdesivir group of requiring 
intervention (OR: 0.90; CI: 0.53–1.53; P = 0.69), with no 
heterogeneity among the studies (I2 = 0%) [Figure 3].
Invasive ventilation or extracorporeal membrane 
oxygenation at day 1 and 14 of the treatment
Three of the four studies presented the data of invasive 
ventilation or ECMO at the 1st day of treatment. 
While the difference was negligible, there was a 
very slight preponderance of the remdesivir group 
to require invasive ventilation or ECMO at day 1 
of the treatment (OR: 1.06; CI: 0.73–1.54; P = 0.77; 
I2 = 28%) [Figure 3].
Three of the four studies reported the data on invasive 
ventilation or ECMO at day 14 of the treatment. Patients 
in the placebo group had a higher likelihood of requiring 
invasive ventilation or ECMO at the 2nd week of the 
treatment as compared to the patients in the remdesivir 
group (OR: 0.39; CI: 0.13–1.14; P = 0.09) [Figure 3]. There 
was moderately high heterogeneity among the studies 
included for the analysis (I2 = 62%).
Figure 2: PRISMA flowchart
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Figure 3: Forrest plots of primary and second outcomes
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Overall serious adverse events after initiation of 
treatment
Three of the four studies reported the data on the 
overall serious adverse effects initiation of treatment, 
and thus, they were included in the meta‑analyses. 
The placebo group had a higher risk or likelihood 
of presenting with adverse outcomes as compared 
to the remdesivir group but with less statistical 
significance (OR: 0.75; CI: 0.55–1.02; P = 0.07) [Figure 3]. There 
was mild heterogeneity between the studies (I2 = 26%).
Discussion
The purpose of the study was to comprehensively 
review the efficacy of remdesivir compared to placebo 
among hospitalized patients with moderate and severe 
COVID‑19. Our inclusion criteria, determined by the 
input of all panel members, were specific for adult 
hospitalized COVID‑19 patients treated with either 
remdesivir or placebo, which distinguishes the findings 
from other meta‑analyses. Based on the analysis of 
four randomized placebo‑controlled trials, the overall 
findings support the use of remdesivir to reduce oxygen 
support, adverse events, and all‑cause mortality after 
5 or 10 days of remdesivir treatment.[5,15,16] Overall, 
the mortality rate for remdesivir‑treated patients 
with COVID‑19 of the three included studies ranged 
1.3%–10% as compared to the 2%–12.5% mortality rates 
of the placebo‑treated patients. This findings were 
consistent with recent clinical data reporting positive 
outcomes for the compassionate use of remdesivir in 
moderate and severe COVID‑19 patients.[11,13,14]
The time to clinical recovery was significantly lower among 
patients who received remdesivir compared to placebo 
across two studies (21 vs. 23 days and 11 vs. 15 days). 
A randomized, open‑label, phase 3 three‑arm trial 
including 584 patients with moderate COVID‑19 
disease compared the efficacy of 5‑ and 10‑day courses 
of remdesivir treatment, compared with standard care. 
The median time to clinical recovery across the 5‑ and 
10‑day treatment course was 6 and 8 days, respectively, 
with recovery in the standard care group being 7 days. 
There were observed differences in the requirements 
of supplemental oxygen with the remdesivir group 
requiring less supplemental oxygen at day 14 than 
the placebo group with day‑1 data, demonstrating 
significant use of supplemental oxygen in the remdesivir 
group. While there was a very slight preponderance of 
the remdesivir group to require the use of high‑flow 
nasal cannula or noninvasive mechanical ventilation 
at day 1, the remdesivir group had reduced likelihood 
of being on invasive ventilation or ECMO at day 14. 
Along with reduced overall oxygen support required 
in the remdesivir group, the all‑cause mortality and 
any adverse events were significantly reduced in 
the remdesivir group in comparison to the placebo 
group. An analysis of 138 healthy volunteers was 
treated with remdesivir, and it appears to have a safe 
clinical profile and is well‑tolerated with transaminase 
elevation identified as the only adverse event.[17] Special 
attention should be given to renal events, pregnancy, 
hypersensitivity reactions, and concomitant vasopressor 
use before remdesivir initiation.[17]
To the best of our knowledge, this is the first meta‑analysis 
and systematic review of remdesivir and control groups, 
which determines oxygen support status at day 1 and 
14, any adverse events at day 14, and all‑cause mortality 
at day 14. We synthesize various clinical outcomes of 
interest using statistical analysis methods that are widely 
applicable and relevant to key stakeholders in healthcare. 
Our results demonstrate that remdesivir use in adults 
may improve in‑hospital mortality, oxygen support 
status and adverse events within 2 weeks of treatment 
initiation. Our findings synthesize the results of primary 
and secondary outcomes of ongoing or completed 
clinical trials.[18‑20] FDA’s press release on August 28, 
2020, broadened the EUA for remdesivir (e.g., Veklury) 
to include all hospitalized patients for the treatment 
of COVID‑19. The scope of existing authorization is 
based on the conclusions that remdesivir is an effective 
treatment option for suspected or laboratory‑confirmed 
COVID‑19 patients in hospitalized settings, with further 
trials required to explore the efficacy according to the 
clinical stratification.
We found over 35 trials registered on the ClinicalTrials.
gov classified as remdesivir group versus placebo group 
using 200 mg loading dose on the 1st day, followed by 
100 mg intravenous once‑daily doses for 5–10 days. The 
outcomes of the ongoing trials are to determine the time 
to clinical improvement, clinical status, time to hospital 
discharge, all‑cause mortality, duration of mechanical 
ventilation, ECMO, supplemental oxygen, length of 
hospital stay, change in viral load assessed by area under 
viral load curve, and the frequency of adverse events.
The baseline health and disease severity were not 
matched in the remdesivir and placebo groups in our 
included studies. In addition, the use of remdesivir 
in high‑risk populations, e.g., elderly age, multiple 
comorbidity, Blacks, and sociodemographic disparity, 
may be considered before moderate or severe COVID‑19 
manifestations occur.[21] The most adequate time of 
administering antiviral treatment is soon after the 
onset of disease to promote benefits, with previous 
reports recommending initiation within 5 or 10 days 
after the onset of symptoms.[14,22,23] Early results based 
on the interim data may lack generalizability, but the 
use of remdesivir has already obtained an approval for 
EUA by the US FDA. The benefits of administrating 
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remdesivir may outweigh the risks in hospitalized 
COVID‑19 patients with oxygen saturation below 94%. 
Patients who have been intubated for a short period 
can also benefit from remdesivir dosage every 24–28 h. 
However, limited clinical effectiveness is expected among 
patients being mechanically ventilated.
In addition, the next steps in finding a consensus 
toward remdesivir use follow the evaluation of potential 
short‑term and long‑term side effects of remdesivir, 
taking into consideration the concomitant use of other 
medication. For instance, the off‑label use of medications 
such as lopinavir–ritonavir, hydroxychloroquine, and 
immunomodulatory drugs including glucocorticoids 
and tocilizumab may confound reports of currently 
promising and beneficial outcomes of remdesivir use.
Recommendations
Reporting biases of currently published trial results 
may be taken into consideration. The clinical benefits 
ought to be predicted within all severity subgroups to 
confer rigorous support for clinical guidance toward 
remdesivir. As the world strives to overcome structural 
and social healthcare disparities, we must accentuate the 
underrepresentation or lack of available data interpreting 
the incidence and clinical outcomes of minority groups 
in the remdesivir COVID‑19 trials.[24] In a preliminary 
cohort study published by Grein et al., data of ethnicity 
were omitted for 53 patients.[11] While the vetting for 
preliminary results was obtained from limited datasets, 
the proportion of Black, Latinx, and Native Americans 
were around 20%, 23%, and 0.7% respectively, in trials 
published by Beigel et al. and Goldman et al.[7,16] In 
addition, while Asia’s population is roughly equivalent 
to 60% of the world population, Spinner et al.’s trial only 
consisted of 17.5% Asian participants.[14] The modest 
benefits in time to clinical improvement post treatment 
may not be generalizable in minority groups due to 
probable differences in severity of disease, outcomes, 
and treatment efficacy. The lack of ethnic diversity in 
clinical studies during the COVID‑19 pandemic ought 
to be addressed at the administrative level by mandating 
the inclusion of minority groups and reporting data at 
the governmental level. A prioritization of populations 
reflecting the demographics of high‑risk groups impacted 
by the ongoing pandemic is crucial, by expanding clinical 
trial sites and employing random sampling.[25]
Limitations
Our findings were limited due to a paucity of available 
data between a 5‑day and a 10‑day course of intravenous 
remdesivir treatment among severe and moderate 
COVID‑19 patients, with only one randomized placebo 
trial reporting these findings. All studies had open‑label 
designs, which potentially led to biases in both patient 
care and reporting of data. Another limitation was the 
lack of corroboration of clinical efficacy with the viral 
loads of the patients in both groups. While the biological 
mechanisms of remdesivir are required to interpret the 
clinical efficacy, not all studies reported the viral loads 
in our meta‑analysis.
Conclusion
Our findings provide strong evidence of clinical 
improvement in randomized, placebo‑controlled 
trials of remdesivir therapy. Implications of our 
meta‑analyses results are strong with a moderately large 
sample size and randomized placebo group. Ongoing 
placebo‑controlled trails employing larger sample sizes 
will remain our informative source of the outcomes 
and adverse events of remdesivir administered to 
hospitalized COVID‑19 patients. Strategies must be used 
to enhance the potency of remdesivir while reducing 
the immunopathological host responses that contribute 
to the infection severity. In addition, the efficacy of 
5 versus 10 days dosing of remdesivir warrants further 
exploration. Our findings suggest that remdesivir merits 
extended clinical use and may also be efficacious among 
nonsevere hospitalized COVID‑19 patients.
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